The firm believes that as Lymphir launches, it will become a value driver for its parent, Citius. Oncology drug Lymphir has achieved significant milestones in its development and approval process ...

Citius Pharma ( (CTXR)) has released its Q4 ... and the accuracy of their predictions so investors know who to trust when making investment decisions.

CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology ... There can be no assurance, however, that this process will result in a strategic transaction or other alternative.